Rx drug tax cut for Macedonia

9 September 2007

The Macedonian government has announced plans to sharply reduce taxes on a range of goods, including drugs and medical appliances, from 18% to 5%. The country's Prime Minister, Nikola Gruevski, informed a press conference that, under the enabling legislation, pharmacies would be obliged to pass on the rebate to consumers.

Mr Gruevski said: "we have a guarantee that the decrease of the prices will be implemented since it is an obligation deriving from the law on medicines, which has already entered the Parliament's revision process."

He added that the tax rebate would reduce government revenues by about 11.0 million euros ($15.0 million) and is in accordance with International Monetary Fund agreements. Macedonia's "gradual but steady growth," the Prime Minister said, had made the decision possible earlier than previously expected. Similar tax cuts for computers and other goods have also been announced in recent days.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight